Prognostic Role of Osteopontin Expression in Malignant Pleural Mesothelioma
|
|
- Nicholas Pitts
- 8 years ago
- Views:
Transcription
1 Anatomic Pathology / Prognostic Role of Osteopontin in Mesothelioma Prognostic Role of Osteopontin Expression in Malignant Pleural Mesothelioma Susanna Cappia, 1 Luisella Righi, MD, PhD, 1 Dario Mirabelli, MD, 2 Paolo Ceppi, 1 Elisa Bacillo, 1 Francesco Ardissone, MD, 1 Luca Molinaro, MD, 1 Giorgio V. Scagliotti, MD, 1 and Mauro Papotti, MD 1 Key Words: Immunohistochemistry; Mesothelioma; Osteopontin; Pleura; Prognosis DOI: /TWCQV536WWRNEU51 Abstract Malignant pleural mesothelioma (MPM) represents highly aggressive neoplasms with a mean survival of approximately 10 months. Osteopontin, a glycoprotein involved in cell-matrix interactions correlated with invasion and metastatic spread in several tumors, has recently been proposed as a serum marker of MPM in asbestos-exposed subjects. The aim of this study was to define the prognostic role of osteopontin in MPM. For the study, 32 long-term survivors (>24 months) and a random sample of 69 short-term survivors ( 24 months) were matched according to the main clinicopathologic features. Immunohistochemical osteopontin expression in tissue specimens was quantified through the HScore (histologic scoring) method and correlated with clinicopathologic parameters and survival. Osteopontin expression was significantly lower in long-term compared with short-term survivors (P <.0001), and overall survival analysis showed that low osteopontin expression was associated with longer survival; multivariate analysis confirmed the value of osteopontin expression as an independent prognostic factor (P <.0001). Malignant pleural mesothelioma (MPM) is a highly lethal tumor associated in the vast majority of the cases with asbestos exposure. The disease is largely unresponsive to conventional chemotherapy or radiotherapy, and surgical treatment (extrapleural pneumonectomy or pleurectomy) has not shown a significant survival benefit compared with supportive treatment. 1 A multimodal approach to improve survival in selected patients remains controversial, and the definition of relevant prognostic factors is lacking. 2 Overall, the median survival time is largely dependent on the tumor stage at diagnosis 3 and in unresectable disease does not exceed 11 months. 4 Long-term survival (>2 years) of patients with MPMs has rarely been reported. 3 Osteopontin is an acidic, calcium-binding glycol-phosphoprotein of 44 to 66 kda, depending on species and cell types. It is found in all body fluids and secreted by osteoclasts, macrophages, cardiac fibroblasts, and activated T cells. 5 Osteopontin binds multiple integrins, including α v β 1, α v β 3, and α v β 5, and it may also be a ligand for some forms of CD44, especially variants 6 and 7. 6,7 Many cellular processes, including cell attachment, spreading and migration, homing of lymphocytes and other hematopoietic cells, and vascular remodeling, are thought to involve osteopontin binding to cell surface receptors. 8,9 Osteopontin is overexpressed in many human tumors, including breast, 10 lung, 11 ovarian, 12 and gastric 13 tumors; hepatocellular carcinomas 14 ; and prostate tumors, 15 and it was proposed as a potential prognostic marker in many of these neoplasms. Osteopontin immunoreactivity is absent in normal mesothelial cells, and it is weakly expressed in reactive mesothelial proliferations. 16,17 Recently, in asbestos-exposed people, high serum levels of osteopontin were correlated with the presence of MPM but not pleural plaques or interstitial lung disease. 16,18 58 Am J Clin Pathol 2008;130: DOI: /TWCQV536WWRNEU51
2 Anatomic Pathology / Original Article The aims of the present study were to investigate the immunohistochemical osteopontin levels in a large series of MPMs and to correlate the results with clinicopathologic parameters. We show that osteopontin reactivity is significantly reduced in long-surviving patients with mesothelioma, expanding its known prognostic role to mesothelial malignancies. Materials and Methods Case Selection All 394 cases diagnosed at the University of Turin Division of Pathology St Luigi Hospital, Turin, Italy, between 1989 and 2003 were identified. All patients were followed up until death or for at least 2 years. The study was limited to data for all patients with survival of more than 24 months (longterm survivors; LS group) and a random sample of patients with survival of less than 24 months (short-term survivors, SS group). Based on follow-up data provided by the Regional Mesothelioma Registry, 70 LS cases were identified. After case review by 2 pathologists (M.P. and L.R.) on H&E-, mucin- (periodic acid Schiff with and without diastase treatment), carcinoembryonic antigen, and calretinin-stained slides, 32 cases from the LS group were retained for the purpose of the study according to the revised histologic diagnosis and available histopathologic (but not cytologic) tissue material; 38 cases were excluded owing to the presence of a cytologic diagnosis only, absent or insufficient archival material in paraffin blocks, or change in the original diagnosis. The SS group was created by randomly selecting from the same database 69 patients with survival of 24 months or less, as commonly observed in most cases, and matched (at least 2 for each LS case) according to sex, age, asbestos exposure (presence, level, type [ie, occupational, household, or environmental], and duration), stage of the disease at thoracoscopy (ie, visceral pleural involvement and presence of vegetating lesions), and histologic tumor type (World Health Organization criteria 19 ). Clinicopathologic data, which were previously prospectively obtained at the Thoracic Surgery Division, St Luigi Hospital, included smoking history, symptoms (cough, dyspnea, and chest pain), latency of development of disease (intended as time between start of exposure and diagnosis), weight loss, performance status, time from symptoms to diagnosis, blood cell count, and treatment administered. All patients underwent talc pleurodesis. A further group of 81 consecutive cases of MPM (CC group) diagnosed at the same institution from January 2005 to June 2007 by thoracoscopic biopsies was also studied for osteopontin expression. Prevalence data of osteopontin reactivity in such unselected cases were compared with those for the LS and SS groups. Finally, pleural biopsy specimens of cases negative for malignancy were obtained and used as control samples for immunohistochemical expression of osteopontin. The study was approved by the St Luigi Hospital Institutional Review Board. All samples were made anonymous by a staff member of the pathology department not involved in the study. None of the researchers who managed the tissues and clinicopathologic features had access to disclosed clinical data. Immunohistochemical Analysis For immunohistochemical analysis, 5-µm-thick paraffin sections of each case were collected onto charged slides, deparaffinized, and rehydrated in water. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide for 15 minutes. Slides were washed and incubated with a blocking reagent (1% bovine serum albumin in tris(hydroxymethyl) aminomethane-buffered saline) for 10 minutes at room temperature to block nonspecific antibody reactions and then reincubated for 40 minutes at room temperature with antihuman osteopontin polyclonal antibody (Sigma Aldrich, Milan, Italy). After a prolonged wash, the slides were incubated with biotin-free polymer preconjugated with goat antirabbit and peroxidase (En Vision Plus antirabbit-hrp system, DakoCytomation, Glostrup, Denmark) at room temperature for 30 minutes. The reaction product was developed with 3-39-diaminobenzidine tetrahydrochloride (DakoCytomation) as the chromogen. The specificity was validated in serial negative control sections by omitting the primary antibody for each immunohistochemical run. The internal reference control was represented by macrophages whenever present. Immunohistochemical Scoring System Immunohistochemical findings were evaluated by two of us (S.C. and E.B.) and cases with contradictory scores were reevaluated jointly and consensus was reached. Osteopontin immunostaining was observed with different intensity in the cytoplasm of mesothelial neoplastic cells and with a different extent of distribution in the tumor. All cases were analyzed by using a semiquantitative histologic scoring (HScore) method, as described in the literature. 20 Briefly, immunostaining intensity of each case was semiquantitatively scored as follows: 0, none; 1, weak; 2, moderate; and 3, intense, referring to the strong intensity of intratumoral macrophages. In addition, the percentage of positive neoplastic cells was evaluated. For each case, a value designed HScore was obtained by multiplying each intensity with the corresponding percentage of positive cells [HScore = Σ(I PC), where I and PC represent intensity and percentage of cells, respectively], obtaining final resulting score values ranging from 0 to 300. Am J Clin Pathol 2008;130: DOI: /TWCQV536WWRNEU51 59
3 Cappia et al / Prognostic Role of Osteopontin in Mesothelioma Statistical Analysis The Mann-Whitney U and the χ 2 tests were used to analyze differential HScore values of osteopontin expression between groups. The median value of the HScore of the pooled LS and SS groups was calculated at 145 and used as a cutoff to select high ( 145) and low (<145) osteopontin-expressing tumors. Survival analysis comparing high with low osteopontin-expressing tumors was performed by Kaplan- Meier curves and the significance verified by log-rank test. Univariate and multivariate analyses of survival were carried out by means of Cox proportional hazards regression modeling. Results were considered statistically significant if the P value was less than.05. Statistical analysis was performed by using Statistica 7.1 software (StatSoft, Tulsa, OK). Results Clinicopathologic Data In the LS group of 32 MPM cases, all subjects survived more than 24 months, with a range of 24.5 to 69.5 months (median, 37.9 months). In this group, the male/female ratio was 20:12, and the median age at diagnosis was 65 years. An asbestos exposure history was identified in 21 (66%) of 32 patients, and the duration of exposure ranged from 2 to 48 years (mean ± SD, 15.9 ± 12.9 years). At thoracoscopy, the visceral pleura was involved by the tumor in 23 cases (72%). Histologically, all but 3 tumors were epithelioid, and the remaining were biphasic MPMs. The mean proliferative index of these cases, as detected by Ki-67 immunostaining, was 12.5%, consistent with previous data. 21 A positive smoking history was reported in 15 patients, and symptoms were distributed as follows: cough, 14 patients; dyspnea, 22; and chest pain, 12. Weight loss of 5% or more was documented in 3 patients; performance status was less than 80% in 4; a platelet count of /µl ( /L) or less was detected in 15 cases; the time from symptoms to diagnosis was less than 4 months in 12 cases. Seven patients received one or more courses of cisplatin-based chemotherapy. The SS group of MPM cases had an overall median survival time of 11.4 months (range, 1-20 months); the male/ female ratio was 50:19, and this group had almost overlapping clinicopathologic features with the matched cases. The median age was 64 years. Information on possible asbestos exposure was available for 51 (74%) of 69 patients; all but 1 were exposed, with a duration of exposure ranging from 1 to 74 years (mean ± SD, 21.2 ± 14.8 years). At thoracoscopy, the visceral pleura was involved by the tumor in 54 (78%) of 69 cases; epithelioid and biphasic histologic features were present in 63 and 6 cases, respectively. The mean proliferative index as detected by Ki-67 immunostaining was 41.2%, consistent with the literature data. 21 Smoking history was positive in 32 of 69 patients. Symptoms were present as follows: cough, 22; dyspnea, 47; and chest pain, 35. Weight loss of 5% or more was documented in 9 cases, performance status was less than 80% in 17, the platelet count was /µl ( /L) or less in 39, and time to diagnosis was less than 4 months in 37. Cisplatin-based chemotherapy was administered to 19 of 69 patients. The consecutive MPM group (CC group) included 60 men and 21 women with a median age of 61 years at diagnosis. Histologically, there were 46 epithelioid, 16 biphasic, and 19 sarcomatoid MPMs. Nonmalignant control cases were represented by cases of normal pleura (spontaneous pneumothorax, 4 cases) and reactive mesothelial hyperplasia (in chronic pleuritis, 4 cases). Immunohistochemical Staining for Osteopontin Osteopontin reactivity was specifically localized in internal control cells (ie, macrophages). No immunoreactivity was observed in normal mesothelial cells obtained from patients with pneumothorax or in the surrounding stroma. Conversely, hyperplastic or reactive mesothelial cells in the cases of nonmalignant chronic pleuritis had weak immunoreactivity. Occasional mesenchymal and inflammatory cells in the extracellular matrix were positive for osteopontin. Osteopontin expression was observed in almost all MPM cases. Neoplastic cells had variable patterns of cytoplasmic reactivity, diffuse granular or as perinuclear spots, with intensity ranging from weak (score 1) to intense (score 3) zimage 1z. The percentage of distribution varied from 1% to 98%; therefore, the HScore values obtained ranged from 1 to 297. In many samples, osteopontin reactivity appeared to be restricted to small, very strong cytoplasmic spots, immediately adjacent to the nucleus. This staining pattern probably corresponds to osteopontin protein in the Golgi apparatus and/or secretory vesicles. 22 In the LS group, the distribution of HScore values of osteopontin expression varied from 5 to 250 (median, 50), whereas in the SS group, HScore values varied from 30 to 297 (median, 180). The difference was statistically significant (P <.0001; Mann-Whitney U) zfigure 1Az. No statistically significant difference (P =.3817; Mann-Whitney U) was found between the pooled LS and SS groups, in which the distribution of HScore values ranged from 5 to 297 (median, 145), and the CC group, ranging from 1 to 285 (median, 132). The two groups were therefore statistically comparable zfigure 1Bz Correlation Analysis of Osteopontin Expression and Clinical and Pathologic Parameters In the LS and SS groups, osteopontin expression had no significant correlation with sex, age, asbestos exposure, thoracoscopic stage, or histologic type. In addition, no correlation with smoking history, symptoms, platelet count, or chemotherapy was observed. In contrast, a significant correlation 60 Am J Clin Pathol 2008;130: DOI: /TWCQV536WWRNEU51
4 Anatomic Pathology / Original Article A C B zimage 1z Osteopontin expression in malignant pleural mesothelioma (MPM). A and B, High histologic scoring (HScore) for immunohistochemical expression of osteopontin was generally observed in short-survival cases of MPM (A and B, immunoperoxidase, 400). C, Most long-survival cases had low HScore osteopontin immunoreactivity, with a lower percentage of positive tumor cells and weaker immunostaining compared with short-survival cases of MPM (immunoperoxidase, 200) LS SS HScore OPN Expression H-Score OPN Expression prognostic factors (P < and P =.02, respectively), whereas no other variables correlated with survival ztable 1z. In multivariate analysis, however, only osteopontin retained significance as an independent predictor of survival. zfigure 2z shows Kaplan-Meier survival curves of patients according to low and high osteopontin expression (log-rank test). B A Discussion LS + SS CC zfigure 1z Distribution of osteopontin (OPN) immunohistochemical histologic scoring (HScore) values in malignant pleural mesothelioma (MPM). A, OPN HScore values were lower in long-term survival (LS) than in short-term survival (SS) cases (P <.0001; Mann-Whitney U). B, OPN HScore values in the pooled LS and SS (LS + SS) cases were comparable to the consecutive MPM group (CC) (P =.3817; Mann-Whitney U). Boxes indicate the range (25th-75th percentiles); whiskers, the major and minor values; and lines in the boxes, median values. between osteopontin expression and weight loss (P =.04; χ2), performance status (P =.006; χ2), and time from symptoms to diagnosis (P =.004; χ2) was recorded. Survival Analysis of Patients With MPM In univariate analyses comparing the LS and SS groups, osteopontin expression and performance status were significant In this study, it was confirmed that osteopontin is expressed in MPM and, for the first time, it was found that its reactivity is significantly reduced in long-term surviving patients. In addition, as previously reported,17 osteopontin expression was also detected in reactive or hyperplastic mesothelial lesions, limiting the proposed diagnostic role in MPM,16 at least at the tissue level. Osteopontin was up-regulated in asbestos-induced tumors developed in a rat model of asbestos carcinogenesis and in cells exposed to asbestos in vitro.23 Recently, osteopontin was proposed as a serum marker of MPM in asbestos-exposed people.16 Based on these observations, a study was designed to assess possible differential osteopontin expression levels in MPM cases having different outcomes. Long survival is a rare event in MPM, accounting for fewer than 18% of the approximately 400 cases seen at St Luigi Hospital. This figure is in agreement with literature data.24,25 Therefore, in this study, data for all MPM cases with long survival were retained, whereas data for only a random sample of comparable short-term survivors were included. 61 Am J Clin Pathol 2008;130: DOI: /TWCQV536WWRNEU51
5 Cappia et al / Prognostic Role of Osteopontin in Mesothelioma ztable 1z Univariate and Multivariate Analysis for Cases of Malignant Pleural Mesothelioma * Univariate Analysis Multivariate Analysis No. of Cases MS HR (Range) P HR (Range) P Sex 0.77 ( ) ( ).62 M F Age (y) 1.02 ( ) ( ).92 < > Smoking 0.96 ( ) ( ).37 No Yes Asbestos exposure Level 1.01 ( ) ( ).71 No Low Intermediate High Duration (y) 0.85 ( ) ( ).22 < Cough 0.93 ( ) ( ).51 No Yes Chest pain 1.2 ( ) ( ).3 No Yes Dyspnea 1.3 ( ) ( ).15 No Yes Weight loss (%) 1.24 ( ) ( ).99 < Performance status (%) 0.55 ( ) ( ).59 < Platelet count ( 10 3 /µl) 0.83 ( ) ( ) > Thoracoscopy 0.97 ( ) ( ).09 Vegetation Plaque Histologic findings 1.02 ( ) ( ).51 Epithelioid Biphasic Chemotherapy 0.93 ( ) ( ).89 No Yes Osteopontin HScore 3.67 ( ) < ( ) < < HR, hazard ratio; HScore, histologic scoring; MS, median survival. * Osteopontin expression is an independent prognostic marker in malignant pleural mesothelioma. Platelet values are given in conventional units; to convert to Système International units ( 10 9 /L), multiply by 1.0. The distinction between long- and short-term survival of patients with MPM was arbitrarily set using a cutoff of 24 months, according to the reported median survival time of 4 to 12 months, with few patients surviving longer than 2 years. 3 We retrospectively identified 32 cases from a long period with survival longer than 24 months. Unfortunately, serum samples were not available for circulating osteopontin measurements, but paraffin blocks from pleural biopsies were retrieved. Each long-surviving MPM case was matched with at least 2 cases of MPMs with similar clinicopathologic characteristics, except for the outcome that followed the expected fatal course within 20 months (mean, 11.1 months). In this latter group, osteopontin expression levels were significantly higher than those of the LS group (P <.0001), a difference maintained also at multivariate analysis, indicating an independent prognostic role of osteopontin in MPM. The 62 Am J Clin Pathol 2008;130: DOI: /TWCQV536WWRNEU51
6 Anatomic Pathology / Original Article Cumulative Proportion Surviving High OPN Time (mo) Low OPN zfigure 2z Cumulative proportion surviving according to osteopontin (OPN) expression. Kaplan-Meier survival curves of patients according to low and high OPN expression (P <.0001; log-rank test). The median histologic scoring (HScore) value of 145 was selected as the cutoff. prevalence of osteopontin expression was also independently assessed in a consecutive series of 81 MPM cases diagnosed by pleural biopsies at St Luigi Hospital, University of Turin, from 2005 to Osteopontin immunoreactivity was detected in the vast majority of cases with focal or low reactivity (HScore <30) in 7 (9%) of 81 cases only and a diffuse and/or strong reactivity in the remaining cases. The prognostic role of osteopontin demonstrated in MPMs is independent of other prognostic factors, such as sex, age, stage, and histologic type. 26 Indeed, the majority of cases in the present study were epithelioid MPMs, which are known to have a better prognosis than the sarcomatoid type. However, within such a subtype, heterogeneity of outcome exists, and osteopontin tissue levels were significantly different in the LS vs SS groups. The tumor proliferative fraction was also found to be of prognostic value; high Ki-67 values were associated with shorter survival. 21 In this study, immunohistochemical analysis was the method used to detect osteopontin, based on previous reports that showed good correlation of immunohistochemical osteopontin expression levels with those of Western blot analysis, enzyme immunoassay, and corresponding messenger RNA analysis. 11,12,27 The osteopontin pattern of distribution was in the form of diffuse granular cytoplasmic reactivity and, more rarely, of paranuclear dots in the Golgi area. 22 This latter pattern was restricted to MPM cases with a poor prognosis (10/69 [14%]). Because osteopontin requires phosphorylation and glycosylation in the Golgi apparatus before being secreted from the cell, the observed punctuate osteopontin staining may reflect increased production and processing of the protein. The assessment of osteopontin immunohistochemical findings by the HScore method 20 takes into account the intensity and percentage of distribution of positive cells. Therefore, with respect to the standard evaluation of immunohistochemical results by a 4-tier score (0-3), it gives a more accurate and homogeneous assessment of the protein expression levels in individual cases. In fact, it allows combining heterogeneous patterns of distribution (eg, diffuse, weak signal and limited areas of strong reactivity), thus reducing the risk of underestimating or overestimating the values for overall protein expression. Increased osteopontin levels have been detected in the plasma or serum derived from patients with a number of solid neoplasms, including ovarian, 12 head and neck, 28 prostate, 29 colon, breast, and lung 30 cancers. Samples from patients with multiple myeloma 31 and MPM 16,18,32 were also found to contain high levels of circulating osteopontin. In MPM, osteopontin serum measurements were shown to be of low diagnostic usefulness owing to the lack of specificity but were of potential value as a prognostic marker together with mesothelin, another product of mesothelial cells. 32 A major limitation of circulating osteopontin measurements is that blood measurements are referred to total osteopontin and do not distinguish osteopontin variants that can be produced by cancer cells, as opposed to normal noncancerous cells. 33 At least 3 splice variants of osteopontin have been identified so far, lacking exon 5 or Osteopontin expression was statistically correlated with a subgroup of long-surviving patients with MPM, as opposed to patients with short survival. These data indicate that increased osteopontin expression levels may be a predictive marker of survival at the time of MPM diagnosis. As a consequence, more aggressive initial therapy or treatments targeting the osteopontin protein with antibodies 35,36 and/or osteopontin receptors by cytotoxic and immunotherapeutic strategies 37,38 may be envisaged. In addition, it is proposed that osteopontin expression be considered as a stratification factor for future trials assessing different treatment modalities in MPM. From the 1 Department of Clinical and Biological Sciences, University of Torino at St Luigi Hospital, Torino, Italy; and 2 Unit of Cancer Epidemiology, CeRMS and CPO-Piemonte, University of Torino, Torino. Supported by grants from the Italian Ministry of Research, Rome (Giorgio V. Scagliotti and Mauro Papotti) and the Regione Piemonte (Progetto Ricerca Sanitaria Finalizzata 2007 DRG n del to Mauro Papotti). Address reprint requests to Dr Mauro Papotti: Dept of Clinical and Biological Sciences, University of Turin, Division of Pathology, St Luigi Hospital, Regione Gonzole 10, Orbassano, Torino, Italy. Acknowledgments: We are grateful to Gianni Bussolati, MD, FRCPath, Piero Borasio, MD, Franco Merletti, MD, and Marco Volante, MD, PhD, University of Turin, for their helpful suggestions. Am J Clin Pathol 2008;130: DOI: /TWCQV536WWRNEU51 63
7 Cappia et al / Prognostic Role of Osteopontin in Mesothelioma References 1. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353: Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21: Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117: van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23: Denhardt DT, Noda M, O Regan AW, et al. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 2001;107: Hu DD, Lin EC, Kovach NL, et al. A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta 5. J Biol Chem. 1995;270: Weber GF, Ashkar S, Glimcher MJ, et al. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science. 1996;271: Senger DR, Perruzzi CA, Gracey CF, et al. Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation. Cancer Res. 1988;48: Shijubo N, Uede T, Kon S, et al. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med. 1999;160: Sharp JA, Sung V, Slavin J, et al. Tumor cells are the source of osteopontin and bone sialoprotein expression in human breast cancer. Lab Invest. 1999;79: Zhang J, Takahashi K, Takahashi F, et al. Differential osteopontin expression in lung cancer. Cancer Lett. 2001;171: Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA. 2002;287: Ue T, Yokozaki H, Kitadai Y, et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer. 1998;79: Gotoh M, Sakamoto M, Kanetaka K, et al. Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int. 2002;52: Forootan SS, Foster CS, Aachi VR, et al. Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer. 2006;118: Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 2005;353: Tigrani DY, Weydert JA. Immunohistochemical expression of osteopontin in epithelioid mesotheliomas and reactive mesothelial proliferations. Am J Clin Pathol. 2007;127: Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelinrelated peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med. 2006;173: Travis WD, Brambilla E, Muller Hermelink HK, et al. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; World Health Organization Classification of Lung Tumours. 20. Huang CI, Kohno N, Ogawa E, et al. Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients. Am J Pathol. 1998;153: Bongiovanni M, Cassoni P, De Giuli P, et al. p27(kip1) immunoreactivity correlates with long-term survival in pleural malignant mesothelioma. Cancer. 2001;92: Packer L, Pavey S, Parker A, et al. Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN. Carcinogenesis. 2006;27: Sandhu H, Dehnen W, Roller M, et al. mrna expression patterns in different stages of asbestos-induced carcinogenesis in rats. Carcinogenesis. 2000;21: Albin M, Magnani C, Krstev S, et al. Asbestos and cancer: an overview of current trends in Europe. Environ Health Perspect. 1999;107(suppl 2): Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma epidemic. Br J Cancer. 1999;79: Spirtas R, Connelly RR, Tucker MA. Survival patterns for malignant mesothelioma: the SEER experience. Int J Cancer. 1988;41: Sakaguchi H, Fujimoto J, Hong BL, et al. Clinical implications of osteopontin in metastatic lesions of uterine cervical cancers. Cancer Lett. 2007;247: Le QT, Sutphin PD, Raychaudhuri S, et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res. 2003;9: Hotte SJ, Winquist EW, Stitt L, et al. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer. 2002;95: Fedarko NS, Jain A, Karadag A, et al. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res. 2001;7: Standal T, Hjorth-Hansen H, Rasmussen T, et al. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma. Haematologica. 2004;89: Grigoriu BD, Scherpereel A, Devos P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res. 2007;13: Vordermark D, Said HM, Katzer A, et al. Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer. 2006;6:207. doi: / Takafuji V, Forgues M, Unsworth E, et al. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene. 2007;26: Bautista DS, Xuan JW, Hota C, et al. Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J Biol Chem. 1994;269: Weber GF, Cantor H. Differential roles of osteopontin/ Eta-1 in early and late lpr disease. Clin Exp Immunol. 2001;126: Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 2000;287: Seiter S, Arch R, Reber S, et al. Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med. 1993;177: Am J Clin Pathol 2008;130: DOI: /TWCQV536WWRNEU51
Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology
Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most are
More informationUpdate on Mesothelioma
November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology Immunohistochemical
More informationL Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
More informationبسم هللا الرحمن الرحيم
بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma
More informationHow To Use An Osteopontin Prognostic Marker In A Cancer
Tropical Journal of Pharmaceutical Research December 2010; 9 (6): 605-613 Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria. All rights reserved. Review Article
More informationImmunohistochemical Expression of Osteopontin in Epithelioid Mesotheliomas and Reactive Mesothelial Proliferations
natomic Pathology / OSTEOPONTIN IN MESOTHELIL PROLIFERTIONS Immunohistochemical Expression of Osteopontin in Epithelioid Mesotheliomas and Reactive Mesothelial Proliferations Dean-Yar Tigrani, MD, and
More informationThe Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin
Anatomic Pathology / TTF-1 IN CYTOLOGY OF BODY FLUIDS The Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin Jonathan L. Hecht, MD,
More informationMesothelioma. Malignant Pleural Mesothelioma
Mesothelioma William G. Richards, PhD Brigham and Women s Hospital Malignant Pleural Mesothelioma 2,000-3,000 cases per year (USA) Increasing incidence Asbestos (50-80%, decreasing) 30-40 year latency
More informationPractical Effusion Cytology
Practical Effusion Cytology A Community Pathologist s Approach to Immunocytochemistry in Body Fluid Cytology Emily E. Volk, MD William Beaumont Hospital Troy, MI College of American Pathologists 2004.
More informationInterest in any of the products, request or order them at Bio-Connect Diagnostics.
MESOMARK, Brochure Interest in any of the products, request or order them at Bio-Connect Diagnostics. Bio-Connect Diagnostics B.V. T NL +31 () 3 T BE +3 () 5 1 53 Begonialaan 3a F NL +31 () 3 1 F BE +3
More informationMalignant Mesothelioma
Malignant Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)
More informationMalignant Mesothelioma
Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)
More informationRecommendations for the Reporting of Pleural Mesothelioma
Recommendations for the Reporting of Pleural Mesothelioma Association of Directors of Anatomic and Surgical Pathology * DOI: 10.1309/6A30YQHBMTHEJTEM It has been evident for decades that pathology reports
More informationMALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY
MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo, Finland 2nd Nordic Conference on Applied
More informationMALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY
MALIGNANT MESOTHELIOMA CLASSIFICATION MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo,
More informationExtrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012
Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro Joon H. Lee 9/17/2012 Malignant Pleural Mesothelioma (Epidemiology) Incidence: 7/mil (Japan) to 40/mil (Australia) Attributed secondary to asbestos
More informationClinical Indications and Results Following Chest Wall Resection
Clinical Indications and Results Following Chest Wall Resection for Recurrent Malignant Pleural Mesothelioma Ali SO, Burt BM, Groth SS, DaSilva MC, Yeap BY, Richards WG, Baldini EH and Sugarbaker DJ. Division
More informationMalignant pleural mesothelioma P/D vs. EPP
3 rd International Thoracic Oncology Congress Dresden, September 13 15, 2012 Malignant pleural mesothelioma P/D vs. EPP Walter Weder, MD Professor of Surgery Dokumentenname Datum Seite 1 Extrapleural Pneumonectomy
More informationUtility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
Imaging, Diagnosis, Prognosis Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment Bogdan-Dragos Grigoriu, 1,6 Arnaud Scherpereel, 1,2 Patrick
More informationScreening, early referral and treatment for asbestos related cancer
Screening, early referral and treatment for asbestos related cancer Marc de Perrot, MD, MSc, FRCSC Toronto Mesothelioma Research Program University of Toronto Asbestos related diseases Mesothelioma Lung
More informationDiagnosis of Mesothelioma Pitfalls and Practical Information
Diagnosis of Mesothelioma Pitfalls and Practical Information Mary Beth Beasley, M.D. Mt Sinai Medical Ctr Dept of Pathology One Gustave L Levy Place New York, NY 10029 (212) 241-5307 mbbeasleymd@yahoo.com
More informationSummary of treatment benefits
Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell
More informationMalignant Mesothelioma: an Update
Malignant Mesothelioma: an Update Nico van Zandwijk Asbestos Diseases Research Institute Bernie Banton Centre University of Sydney Australia Physicians Week RACP 19-5-2009 Health Risks of Asbestos Fibers
More informationMesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology
MesoPDT Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI Image Assisted Laser Therapy for Oncology Unité Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI "Image
More informationMalignant Mesothelioma State of the Art
Malignant Mesothelioma State of the Art Paul Baas The Netherlands Cancer Institute August 12, 2011, Carlsbad, CA Summary Diagnosis; epithelial type subdivided Pleiomorphic vs other Staging: IASLC-IMIG
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationTumour Markers. What are Tumour Markers? How Are Tumour Markers Used?
Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or
More informationTargeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma
The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.
More informationA 70-year old Man with Pleural Effusion
Mesothelioma Diagnosis: Pitfalls and Latest Updates S Klebe and DW Henderson Recommendations Indisputable malignant cells on cytomorphological criteria which demonstrate a mesothelial phenotype, which
More informationMaterials and Methods. Results
Anatomic Pathology / Malignant Pleural Mesothelioma Histologic Assessment and Prognostic Factors of Malignant Pleural Mesothelioma Treated With Extrapleural Pneumonectomy Andrea V. Arrossi, MD, 1 E. Lin,
More informationMalignant Pleural Mesothelioma in Singapore
RESEARCH COMMUNICATION C SP Yip 1, HN Koong 2, CM Loo 3, KW Fong 1* Abstract Aim: To examine the clinical characteristics and outcomes of malignant pleural mesothelioma (MPM) in Singapore. Methods and
More informationREPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM
REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM Valerie Van Damme, Isabelle Wauters, Johan Vansteenkiste Univ. Hospital Leuven and Leuven Lung Cancer Group Introduction Perspectives in Lung Cancer (PILC)
More informationMalignant Mesothelioma Current Approaches to a Difficult Problem. Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center
Malignant Mesothelioma Current Approaches to a Difficult Problem Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center Malignant Pleural Mesothelioma Clinical Presentation Insidious
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3
ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3 HOW TO CITE THIS ARTICLE: Gorantla Sambasivarao, Namballa Usharani,
More informationINTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project Data Forms and Fields in CRAB Electronic Data Capture System - Reduced Set - Pivotal data elements for developing
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationKomorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
More informationHER2 Status: What is the Difference Between Breast and Gastric Cancer?
Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC
More informationCharacteristics of Malignant Pleural Mesothelioma in Women
Characteristics of Malignant Pleural Mesothelioma in Women Andrea S. Wolf, MD, MPH, William G. Richards, PhD, Tamara R. Tilleman, MD, PhD, Lucian Chirieac, MD, Shelley Hurwitz, PhD, Raphael Bueno, MD,
More informationRare Thoracic Tumours
Rare Thoracic Tumours 1. Epithelial Tumour of Trachea 1 1.1 General Results Table 1. Epithelial Tumours of Trachea: Incidence, Trends, Survival Flemish Region 2001-2010 Both Sexes Incidence Trend EAPC
More informationObjectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background
Imaging of Pleural Tumors Mylene T. Truong, MD Imaging of Pleural Tumours Mylene T. Truong, M. D. University of Texas M.D. Anderson Cancer Center, Houston, TX Objectives To review tumors involving the
More informationThe develpemental origin of mesothelium
Mesothelioma Tallinn 14.12.06 Henrik Wolff Finnish Institute of Occupational Health The develpemental origin of mesothelium Mesodermal cavities (pleura, peritoneum and pericardium ) are lined with mesenchymal
More informationSeattle. Case Presentations. Case 1. 76 year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion.
Seattle Montreal IAP September 2006 Case Presentations Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Clinical Professor of Pathology University of British Columbia Case
More informationSurgical therapy of. who should be operated
SAMO Interdisciplinary Workshop on Chest Tumors Lucerne, 13th and 14th January 2012 Surgical therapy of mesothelioma, who should be operated Walter Weder MD Professor of Surgery University Hospital Zurich
More informationSurvey of Mesothelioma Associated with Asbestos Exposure in Japan
The research and development and the dissemination projects related to the 13 fields of occupational injuries and illnesses Survey of Mesothelioma Associated with Asbestos Exposure in Japan Clinical characteristics
More informationH. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland School of Medicine Baltimore, Md
Major Advances in Cancer Prevention, Diagnosis and Treatment~ Why Mesothelioma Leads the Way H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland
More informationPre-workshop exercise
Setting research priorities for mesothelioma workshop 10 th November 2014 Pre-workshop exercise Your individual ranking of unanswered questions about the diagnosis, treatment and care of mesothelioma Please
More informationCytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium
Cytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium Introduction 3 cavities with the same embryologic origin the mesoderme Pleura Exudates Pleura Peritoneum Pericardium 22%
More informationmicrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved
microrna 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions of target mrnas Act as negative
More informationPopulation-based survival for malignant mesothelioma after introduction of novel chemotherapy
Eur Respir J 2012; 40: 185 189 DOI: 10.1183/09031936.00153611 CopyrightßERS 2012 Population-based survival for malignant mesothelioma after introduction of novel chemotherapy Ronald A.M. Damhuis*, Caroline
More informationNon-invasive diagnosis of pleural malignancies: The role of tumour markers
Lung Cancer (2008) 59, 350 354 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/lungcan Non-invasive diagnosis of pleural malignancies: The role of tumour markers Michel M.
More informationDiagnostic Challenge. Department of Pathology,
Cytology of Pleural Fluid as a Diagnostic Challenge Paavo Pääkkö,, MD, PhD Chief Physician and Head of the Department Department of Pathology, Oulu University Hospital,, Finland Oulu University Hospital
More informationLung Cancer: More than meets the eye
Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research
More informationMale. Female. Death rates from lung cancer in USA
Male Female Death rates from lung cancer in USA Smoking represents an interesting combination of an entrenched industry and a clearly drug-induced cancer Tobacco Use in the US, 1900-2000 5000 100 Per Capita
More informationDIAPHRAGM. DIAgnostic and Prognostic biomarkers in the Rational Assessment of Mesothelioma
DIAPHRAGM DIAgnostic and Prognostic biomarkers in the Rational Assessment of Mesothelioma Kevin Blyth Consultant Respiratory Physician, Southern General Hospital NRS Research Fellow & Honorary Clinical
More informationColumbia University Mesothelioma Applied Research Foundation - 2009 - www.curemeso.org. Mesothelioma Center www.mesocenter.org
Columbia University Mesothelioma Center www.mesocenter.org Multimodal clinical trials, treatment (surgery, radiation, chemotherapy) Peritoneal mesothelioma program Immunotherapy translational, experimental
More informationLung Cancer. Public Outcomes Report. Submitted by Omar A. Majid, MD
Public Outcomes Report Lung Cancer Submitted by Omar A. Majid, MD Lung cancer is the most common cancer-related cause of death among men and women. It has been estimated that there will be 226,1 new cases
More informationChanges in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred
More informationMeasures of Prognosis. Sukon Kanchanaraksa, PhD Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationSternotomy and removal of the tumor
Sternotomy and removal of the tumor All thymomas originate from epithelial thymic cells 4% of them consist of a pure population of epithelial cells Most have mixed populations of lymphoid cells to a
More informationClinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines
Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines Wieneke Buikhuisen The Netherlands Cancer Institute Amsterdam The Netherlands Case (1) Male, 56 year
More informationPATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry. M. Praet
PATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry M. Praet Pathology of the Pleura Normal serosa: visceral and parietal layers Inflammation Neoplasia: Primary: mesothelioma
More informationPost-operative intrapleural chemotherapy for mesothelioma
Post-operative intrapleural chemotherapy for mesothelioma Robert Kratzke, MD John Skoglund Chair for Lung Cancer Research Section of Heme-Onc-Transplant University of Minnesota Medical School Efficacy
More informationThe diagnostic usefulness of tumour markers CEA and CA-125 in pleural effusion
Malaysian J Path01 2002; 24(1) : 53-58 The diagnostic usefulness of tumour markers CEA and CA-125 in pleural effusion Pavai STHANESHWAR MD, Sook-Fan YAP FRCPath, FRCPA and Gita JAYARAM MDPath, MRCPath
More informationPROTOCOL OF THE RITA DATA QUALITY STUDY
PROTOCOL OF THE RITA DATA QUALITY STUDY INTRODUCTION The RITA project is aimed at estimating the burden of rare malignant tumours in Italy using the population based cancer registries (CRs) data. One of
More informationReport series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
More informationEffects of Herceptin on circulating tumor cells in HER2 positive early breast cancer
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine
More informationAdvances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope
Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope Daniel H. Sterman, M.D. Associate Professor of Medicine and Surgery Co-Director, PENN Mesothelioma and Pleural Program University
More informationPRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT
PRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT Dott. Francesco Pontieri (*) U.O. di Anatomia Patologica P.O. di Rossano (CS) Dott. Gian Franco Zannoni Anatomia Patologica Facoltà di Medicina e Chirurgia
More informationMalignant Mesothelioma Recent Advances
Malignant Mesothelioma Recent Advances Dr AS Paul 04 Aug 06 DM Seminar Malignant mesothelioma A tumour of serosal surfaces Pleura, peritoneum Increasing incidence worldwide Association with asbestos exposure
More informationReport on New Patented Drugs - Alimta
Report on New Patented Drugs - Alimta Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the PMPRB s Excessive
More informationNon Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress
Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Lung Cancer Accounts for 14% of All New Cancer Diagnoses in the United States 1 Lung cancer is the second most common malignancy
More informationDetection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical
Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent
More informationBrigham and Women s Hospital, Boston, MA, USA; 2 Verastem, Inc., Boston, MA, USA
Determination of Biomarker Response in a Phase II Window of Opportunity Study of Defactinib (VS 6063), a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Resectable Malignant Pleural Mesothelioma
More informationIntroduction Objective Methods Results Conclusion
Introduction Objective Methods Results Conclusion 2 Malignant pleural mesothelioma (MPM) is the most common form of mesothelioma a rare cancer associated with long latency period (i.e. 20 to 40 years),
More informationPrimary -Benign - Malignant Secondary
TUMOURS OF THE LUNG Primary -Benign - Malignant Secondary The incidence of lung cancer has been increasing almost logarithmically and is now reaching epidemic levels. The overall cure rate is very low
More informationNew strategies in anticancer therapy
癌 症 診 療 指 引 簡 介 及 臨 床 應 用 New strategies in anticancer therapy 中 山 醫 學 大 學 附 設 醫 院 腫 瘤 內 科 蔡 明 宏 醫 師 2014/3/29 Anti-Cancer Therapy Surgical Treatment Radiotherapy Chemotherapy Target Therapy Supportive
More informationResearch Article Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma
Disease Markers Volume 2015, Article ID 282145, 5 pages http://dx.doi.org/10.1155/2015/282145 Research Article Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma Emanuela Taioli,
More informationHow To Treat Mesothelioma With A Tumor Stem Cell Inhibitor
FAK INHIBITOR DEFACTINIB (VS-6063) TARGETS MESOTHELIOMA CANCER STEM CELLS Rationale for maintenance therapy after conventional therapy Jonathan Pachter, Ph.D. Vice President of Research, Verastem, Inc.
More informationOutline. Workup for metastatic breast cancer. Metastatic breast cancer
Metastatic breast cancer Immunostain Update: Diagnosis of metastatic breast carcinoma, emphasizing distinction from GYN primary 1/3 of breast cancer patients will show metastasis 1 st presentation or 20-30
More informationJ of Evidence Based Med & Hlthcare, pissn- 2349-2562, eissn- 2349-2570/ Vol. 2/Issue 33/Aug. 17, 2015 Page 5063
PERITONEAL MALIGNANT MESOTHELIOMA: A RARE S. R. Dhamotharan 1, S. Shanthi Nirmala 2, F. Celine Foustina Mary 3, M. Arul Raj Kumar 4, R. Vinothprabhu 5 HOW TO CITE THIS ARTICLE: S. R. Dhamotharan, S. Shanthi
More informationPSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.
PSA Testing 101 Stanley H. Weiss, MD Professor, UMDNJ-New Jersey Medical School Director & PI, Essex County Cancer Coalition weiss@umdnj.edu September 23, 2010 Screening: 3 tests for PCa A good screening
More informationThe evolving pathology of solitary fibrous tumours. Luciane Dreher Irion MREH / CMFT / NSOPS
The evolving pathology of solitary fibrous tumours Luciane Dreher Irion MREH / CMFT / NSOPS Historical review Haemangiopericytoma (HPC) first described primarily as a soft tissue vascular tumour of pericytic
More informationSurgery. Wedge resection only part of the lung, not. not a lobe, is removed. Cancer Council NSW
The treatment you receive will depend on your lung cancer type, for example, whether you have a non-small cell lung cancer Adenocarcinoma or Squamous cell carcinoma, and if this is a sub-type with a mutation.
More informationMalignant pleural mesothelioma: outcome of limited surgical management
Interactive Cardiovascular and Thoracic Surgery 2 (2003) 30 34 Institutional review Thoracic general Malignant pleural mesothelioma: outcome of limited surgical management Peter G. Phillips a, George Asimakopoulos
More informationprognostic scoring systems. We
Thorax 2000;55:731 735 731 Original articles Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems J G Edwards, K R Abrams, J N Leverment,
More informationEvaluation of asbestos-exposure, clinical diagnosis and treatment of MPM
Evaluation of asbestos-exposure, clinical diagnosis and treatment of MPM Aija Knuuttila, MD, PhD Dept. of Pulmonary Medicine Helsinki University Central Hospital, Finland 15.11.2007 Malignant pleural mesothelioma
More informationMesothelioma: Questions and Answers
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Mesothelioma: Questions
More informationLung cancer is not just one disease. There are two main types of lung cancer:
1. What is lung cancer? 2. How common is lung cancer? 3. What are the risk factors for lung cancer? 4. What are the signs and symptoms of lung cancer? 5. How is lung cancer diagnosed? 6. What are the available
More informationYOUR LUNG CANCER PATHOLOGY REPORT
UNDERSTANDING YOUR LUNG CANCER PATHOLOGY REPORT 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT 1 CONTENTS What is a Pathology Report?...3 The Basics...4 Sections of a Pathology Report...7
More informationPost-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence
Post- survival in completely resected stage I non-small cell lung cancer with local J-J Hung, 1,2,3 W-H Hsu, 3 C-C Hsieh, 3 B-S Huang, 3 M-H Huang, 3 J-S Liu, 2 Y-C Wu 3 See Editorial, p 185 c A supplementary
More informationTreatment of mesothelioma in Bloemfontein, South Africa
European Journal of Cardio-thoracic Surgery 24 (2003) 434 440 www.elsevier.com/locate/ejcts Treatment of mesothelioma in Bloemfontein, South Africa W.J. de Vries*, M.A. Long Cardiothoracic Department,
More informationERCC1 as a Biological Marker Guiding Management in Malignant Pleural Mesothelioma
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.10.4117 RESEARCH ARTICLE ERCC1 as a Biological Marker Guiding Management in Malignant Pleural Mesothelioma Yasemin Benderli Cihan 1 *, Ahmet Ozturk², Alaettin
More informationSurgeons Role in Symptom Management. A/Prof Cliff K. C. Choong Consultant Thoracic Surgeon Latrobe Regional Hospital GIPPSLAND
Surgeons Role in Symptom Management A/Prof Cliff K. C. Choong Consultant Thoracic Surgeon Latrobe Regional Hospital GIPPSLAND Conditions PLEURAL Pleural effusion Pneumothorax ENDOBRONCHIAL Haemoptysis
More informationHistorical Basis for Concern
Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical
More informationRound Table with Drs. Anne Tsao and Alex Farivar, Case 2: Mesothelioma
Round Table with Drs. Anne Tsao and Alex Farivar, Case 2: Mesothelioma I d like to welcome everyone, thanks for coming out to our lunch with experts. The faculty today are great people in the thoracic
More informationSurvival analysis of 220 patients with completely resected stage II non small cell lung cancer
窑 Original Article 窑 Chinese Journal of Cancer Survival analysis of 22 patients with completely resected stage II non small cell lung cancer Yun Dai,2,3, Xiao Dong Su,2,3, Hao Long,2,3, Peng Lin,2,3, Jian
More informationThe Need for Accurate Lung Cancer Staging
The Need for Accurate Lung Cancer Staging Peter Baik, DO Thoracic Surgery Cancer Treatment Centers of America Oklahoma Osteopathic Association 115th Annual Convention Financial Disclosures: None 2 Objectives
More information